Cargando…
PARP-1 inhibition with or without ionizing radiation confers reactive oxygen species-mediated cytotoxicity preferentially to cancer cells with mutant TP53
Biomarkers and mechanisms of poly (ADP-ribose) polymerase (PARP) inhibitor-mediated cytotoxicity in tumor cells lacking a BRCA-mutant or BRCA-like phenotype are poorly defined. We sought to explore the utility of PARP-1 inhibitor (PARPi) treatment with/without ionizing radiation in muscle-invasive b...
Autores principales: | Liu, Qi, Gheorghiu, Liliana, Drumm, Michael, Clayman, Rebecca, Eidelman, Alec, Wszolek, Matthew F., Olumi, Aria, Feldman, Adam, Wang, Meng, Marcar, Lynnette, Citrin, Deborah E., Wu, Chin-Lee, Benes, Cyril H., Efstathiou, Jason A., Willers, Henning |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5970015/ https://www.ncbi.nlm.nih.gov/pubmed/29511347 http://dx.doi.org/10.1038/s41388-018-0130-6 |
Ejemplares similares
-
Acquired Resistance of EGFR-Mutated Lung Cancer to Tyrosine Kinase Inhibitor Treatment Promotes PARP Inhibitor Sensitivity
por: Marcar, Lynnette, et al.
Publicado: (2019) -
TP53 mutation status: emerging biomarker for precision radiation medicine?
por: Willers, Henning, et al.
Publicado: (2018) -
Self-Retraction Clamp for Dissection of the Posterior Prostatic Fossa During Radical Retropubic Prostatectomy
por: Olumi, Aria F.
Publicado: (2004) -
Preferential potentiation of topoisomerase I poison cytotoxicity by PARP inhibition in S phase
por: Znojek, P, et al.
Publicado: (2014) -
Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing’s Sarcoma
por: Gill, Sonja J., et al.
Publicado: (2015)